SCHEMBL1642090

SCHEMBL1642090

CCN(CC)CCOc1cccc(Nc2nccc(-c3scnc3-c3cccc(NC(=O)c4cc(F)ccc4F)c3)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.47
IGF1R P08069 8/20 0.46
AGER Q15109 1/20 0.46
INSR P06213 1/20 0.45
ABL1 P00519 3/20 0.44
BCR P11274 3/20 0.44
EGFR P00533 3/20 0.44
ERBB2 P04626 2/20 0.44
PDGFRB P09619 2/20 0.42
PDGFRA P16234 2/20 0.42
PRKCA P17252 1/20 0.42
CDK2AP1 O14519 1/20 0.41
CHEK1 O14757 1/20 0.41
MET P08581 1/20 0.41
BRAF P15056 1/20 0.40
CDC7 O00311 1/20 0.40
CDK19 Q9BWU1 1/20 0.40
JAK2 O60674 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641931 0.93 IGF1R (0.53) SLC2A1IGF1RINSRABL1BCR
SCHEMBL13816259 0.91 SLC2A1 (0.56) SLC2A1IGF1RAGERINSRABL1
Formic Acid SCHEMBL1642003 0.89 SLC2A1 (0.54) SLC2A1IGF1RAGERINSRABL1
SCHEMBL12766485 0.84 IGF1R (0.56) SLC2A1IGF1RINSREGFRERBB2
SCHEMBL1641883 0.83 AGER (0.45) SLC2A1IGF1RAGERINSRABL1
Formic Acid SCHEMBL1641976 0.82 IGF1R (0.54) SLC2A1IGF1RINSREGFRERBB2
SCHEMBL1642000 0.81 IGF1R (0.43) SLC2A1IGF1RAGERINSRABL1
SCHEMBL1641537 0.80 SLC2A1 (0.55) SLC2A1IGF1RAGERINSRABL1
SCHEMBL12726574 0.80 ABL1 (0.43) SLC2A1IGF1RABL1BCREGFR
SCHEMBL1642023 0.78 LCLAT1 (0.47) ABL1BCREGFRERBB2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 SLC2A1 2698/4885IGF1R 396/4885AGER 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.